ER+ tumors reclassified by BluePrint as Basal-type occur at a Read More
PUBLICATION: ASCO 2021 Authors Joyce O’Shaughnessy1, Virginia G. Kaklamani2, Read More
PUBLICATION: ASCO 2021 Authors Cathy Graham1, Douglas K. Marks2, Read More
PUBLICATION: ASCO 2021 Authors Nina D’Abreo1,2, Abhinav Rohatgi1,2, Douglas Read More
MammaPrint was the only test to predict significant 36% and Read More
Oral presentation at ASCO 2021 highlights long term data with Read More
Transcriptomic differences found between Luminal tumors in African American and Read More
Transcriptomic differences found between Luminal tumors in African American and Read More
Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Read More
Publication: St. Gallen Authors: Jennifer A. Crozier, Lisa Blumencranz, Read More
Contact
For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com
For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com
© 2021 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.
